209 related articles for article (PubMed ID: 2105682)
1. Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Prewitt RM; Hoy C; Kong A; Gu SA; Greenberg D; Cook R; Chan SM; Ducas J
Am Rev Respir Dis; 1990 Feb; 141(2):290-5. PubMed ID: 2105682
[TBL] [Abstract][Full Text] [Related]
2. Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Gu S; Ducas J; Patton JN; Greenberg D; Prewitt RM
Chest; 1992 Jun; 101(6):1684-90. PubMed ID: 1600792
[TBL] [Abstract][Full Text] [Related]
3. Effects of flow on recombinant tissue plasminogen activator-induced pulmonary thrombolysis.
Prewitt RM; Gu SA; Greenberg D; Chan SM; Schick U; La Pointe H; Ducas J
J Appl Physiol (1985); 1991 Oct; 71(4):1441-6. PubMed ID: 1757368
[TBL] [Abstract][Full Text] [Related]
4. Principles of thrombolysis in pulmonary embolism.
Prewitt RM
Chest; 1991 Apr; 99(4 Suppl):157S-164S. PubMed ID: 2009813
[TBL] [Abstract][Full Text] [Related]
5. Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Werier J; Ducas J; Gu S; Chan SM; Prewitt RM
Chest; 1991 Aug; 100(2):464-9. PubMed ID: 1650681
[TBL] [Abstract][Full Text] [Related]
6. [Experimental study of the thrombolytic effects in a canine model of pulmonary thromboembolism induced by autologous radioactive blood clots].
Wang F; Wang C; Wang T; Pang BS; Wu YB; Yang YH; Li C; Zhang HY; Weng XZ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Feb; 27(2):93-6. PubMed ID: 14990182
[TBL] [Abstract][Full Text] [Related]
7. Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Prewitt RM; Downes AM; Gu SA; Chan SM; Ducas J
Chest; 1991 Mar; 99(3):708-14. PubMed ID: 1899825
[TBL] [Abstract][Full Text] [Related]
8. [Pulmonary embolism: which thrombolytic should be chosen?].
Pacouret G; Augusseau-Richard MP; Dessenne X; Pagot O; Charbonnier B
Arch Mal Coeur Vaiss; 1995 Nov; 88(11 Suppl):1763-7. PubMed ID: 8815837
[TBL] [Abstract][Full Text] [Related]
9. Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics.
Prewitt RM; Shiffman F; Greenberg D; Cook R; Ducas J
Circulation; 1989 Apr; 79(4):929-38. PubMed ID: 2494007
[TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator in acute pulmonary embolism.
Goldhaber SZ
Chest; 1989 May; 95(5 Suppl):282S-289S. PubMed ID: 2495913
[TBL] [Abstract][Full Text] [Related]
11. Intravenous administration of recombinant tissue plasminogen activator. Optimizing the rate of coronary thrombolysis.
Prewitt RM; Gu S; Schick U; Ducas J
Chest; 1995 Apr; 107(4):1146-51. PubMed ID: 7705128
[TBL] [Abstract][Full Text] [Related]
12. [The value of thrombolysis for the treatment of acute pulmonary embolism].
Marbet GA
Schweiz Med Wochenschr; 1989 Oct; 119(43):1498-505. PubMed ID: 2514456
[TBL] [Abstract][Full Text] [Related]
13. [The thrombolytic treatment of acute and subacute recurrent pulmonary embolism with recombinant tissue plasminogen activator].
Tiede N; Kasper W; Geibel A; Bassenge D; Langenstein B; Meinertz T; Just H
Dtsch Med Wochenschr; 1990 Nov; 115(45):1699-704. PubMed ID: 2121453
[TBL] [Abstract][Full Text] [Related]
14. Optimizing coronary thrombolysis with i.v. administration of recombinant tissue plasminogen activator. Single bolus vs double bolus vs front-loading.
Prewitt RM; Schick U; Ducas J
Chest; 1996 Feb; 109(2):510-5. PubMed ID: 8620730
[TBL] [Abstract][Full Text] [Related]
15. Accelerated ST-segment reduction after thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) compared to urokinase.
Derad I; Stierle U; Giannitsis E; Potratz J; Born J; Djonlagic H; Fehm HL
Jpn Heart J; 1996 Jan; 37(1):33-41. PubMed ID: 8632624
[TBL] [Abstract][Full Text] [Related]
16. Effect of recombinant single-chain urokinase-type plasminogen activator on experimental pulmonary embolism.
Yang Wang ; Chen Wang ; Yuanhua Yang ; Baosen Pang
Clin Appl Thromb Hemost; 2010 Oct; 16(5):537-42. PubMed ID: 19833628
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial.
Mahler F; Schneider E; Hess H;
J Endovasc Ther; 2001 Dec; 8(6):638-47. PubMed ID: 11797982
[TBL] [Abstract][Full Text] [Related]
18. Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Zhu L; Wang C; Yang Y; Wu Y; Zhai Z; Dai H; Pang B; Tong Z
J Thromb Thrombolysis; 2008 Dec; 26(3):251-6. PubMed ID: 17705052
[TBL] [Abstract][Full Text] [Related]
19. Effects of recombinant tissue-type plasminogen activator on life-threatening acute pulmonary thromboembolism in a canine model: a comparative study of e6010 and alteplase.
Tagami H; Utoh J; Sun LB; Okamoto K; Moriyama S; Kunitomo R; Kitamura N
Ann Thorac Cardiovasc Surg; 2000 Oct; 6(5):299-303. PubMed ID: 11173335
[TBL] [Abstract][Full Text] [Related]
20. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.
Goldhaber SZ; Kessler CM; Heit JA; Elliott CG; Friedenberg WR; Heiselman DE; Wilson DB; Parker JA; Bennett D; Feldstein ML
J Am Coll Cardiol; 1992 Jul; 20(1):24-30. PubMed ID: 1607532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
